Anzeige
Mehr »
Login
Samstag, 02.12.2023 Börsentäglich über 12.000 News von 684 internationalen Medien
Trend 2024: Reich werden mit dieser Nickel-Aktie?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7JK | ISIN: AU000000TLX2 | Ticker-Symbol: T3X
Tradegate
01.12.23
21:26 Uhr
6,020 Euro
+0,016
+0,27 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
TELIX PHARMACEUTICALS LIMITED Chart 1 Jahr
5-Tage-Chart
TELIX PHARMACEUTICALS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
5,8806,12813:00
5,8806,12801.12.

Aktuelle News zur TELIX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiTelix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS391MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated...
► Artikel lesen
DiTELIX PHARMACEUTICALS LIMITED: Cleansing Notice-
DiTELIX PHARMACEUTICALS LIMITED: Application for quotation of securities - TLX1
21.11.Jefferies sees potential for Australia's Telix Pharmaceuticals' acquisitions10
16.11.TELIX PHARMACEUTICALS LIMITED: Telix ProstACT (TLX591) Expert Forum - Webcast Notification8
14.11.Telix plans $125m acquisition of radiopharmaceuticals company QSAM5
14.11.Telix offers $33M to acquire Qsam for phase 1 bone cancer radiopharmaceutical3
14.11.QSAM Biosciences signs term sheet to be acquired by Telix Pharmaceuticals2
14.11.QSAM Biosciences Inc.: QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee129Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...
► Artikel lesen
14.11.Telix Pharmaceuticals to acquire private US bone cancer firm QSAM Biosciences8
14.11.Australia's Telix gains on deal to acquire based therapeutic firm2
13.11.Telix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®503MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences...
► Artikel lesen
13.11.Telix Pharmaceuticals Limited: Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery394MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea Technologies (Euronext Growth: ALMKT,...
► Artikel lesen
13.11.Mauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic Surgery338Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a ~19% stake in Mauna Kea Technologies through a €6 million equity investment Regulatory...
► Artikel lesen
13.11.Telix Pharmaceuticals Limited: First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591393MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase...
► Artikel lesen
12.11.TELIX PHARMACEUTICALS LIMITED: Telix Announces Proposed Acquisition of QSAM Biosciences-
12.11.TELIX PHARMACEUTICALS LIMITED: First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study2
08.11.TELIX PHARMACEUTICALS LIMITED: Cleansing Notice2
08.11.TELIX PHARMACEUTICALS LIMITED: Application for quotation of securities - TLX-
08.11.Telix Pharmaceuticals Limited: Telix to Present at Jefferies London Healthcare Conference 2023389MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO...
► Artikel lesen
Seite:  Weiter >>
105 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1